文献速递瓣膜外科

供体三尖瓣修复与心脏移植结局的关联

Association of Donor Tricuspid Valve Repair With Outcomes After Cardiac Transplantation.
PubMed 文献 · Ann Thorac Surg · 2017-11-23

本研究纳入2002至2016年间330例心脏移植患者,其中173例(52.4%)接受供体三尖瓣修复(dTVR),采用多变量Cox回归及倾向性评分分析dTVR与死亡、移植后三尖瓣修复、心脏移植后肾移植或慢性透析复合结局的关联。结果显示dTVR组复合结局发生率较低(22.5% vs 36.4%,p=0.006),但多变量模型未显示显著关联,无显著获益或 harm。

要点

  • dTVR与复合结局(死亡、移植后TVR、肾移植或透析)在多变量分析中无显著关联。
  • dTVR组复合结局发生率较低(22.5% vs 36.4%,p=0.006),但未经多变量校正。
  • 移植后第一年活检次数越多复合结局风险越低,高级别活检和肌酐升高则风险更高。

核心结论

  • dTVR与死亡、移植后TVR或透析的复合结局无显著获益或 harm。

研究设计与样本

  • 采用多变量Cox回归模型,并纳入倾向性评分以控制接受dTVR基线可能性的差异。

主要发现

  • dTVR组复合结局发生39例(22.5%),无dTVR组56例(36.4%),p=0.006。
  • 多变量建模中dTVR与复合结局无显著关联。
  • 移植后第一年活检次数较多与复合结局风险降低相关。
  • 更高级别活检标本和较高肌酐与复合结局风险升高相关。

关键数值与推荐

  • 复合结局包括死亡、移植后TVR、心脏移植后肾移植或慢性透析。
  • dTVR实施率随时间和外科医生变化,2011年1月1日至2013年11月30日期间实施71例(83.5%)。

临床怎么用

  • 供体三尖瓣修复对心脏移植后复合结局无显著获益或 harm,临床决策需个体化。
  • 移植后第一年活检次数较多与较低复合结局风险相关,高级别活检和肌酐升高提示风险增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tricuspid regurgitation after cardiac transplantation is associated with worse clinical outcomes. This study sought to determine the association of donor tricuspid valve repair (dTVR) with outcomes after cardiac transplantation. METHODS: Patients who underwent cardiac transplantation between January 20, 2002, and December 31, 2016, were included. Multivariable Cox regression modeling was performed to determine the association between dTVR and the composite outcome of death, posttransplant TVR, kidney transplant after cardiac transplant, or chronic dialysis, and included propensity scoring to control for baseline differences in likelihood of undergoing dTVR. RESULTS: The analysis included 330 patients, with 173 (52.4%) undergoing dTVR. dTVR performance varied by surgeon and also increased over time, with 71 (83.5%) performed during January 1, 2011, to November 30, 2013. Transplant year and surgeon were significantly associated with the baseline likelihood of undergoing dTVR. Although fewer composite outcomes occurred in the dTVR vs no dTVR group (39 [22.5%] vs 56 [36.4%], p = 0.006), dTVR was not significantly associated with the composite outcome in multivariable modeling. Lower risk for the composite outcome was associated with greater number of biopsies during the first posttransplant year, whereas higher risk was associated with more high-grade biopsy specimens and higher creatinine. CONCLUSIONS: There was no significant benefit or harm with regards to the composite of death, posttransplant TVR, or dialysis associated with dTVR.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Greenberg J, Teman NR, Haft JW, et al. Association of Donor Tricuspid Valve Repair With Outcomes After Cardiac Transplantation. Ann Thorac Surg. 2017. PMID: 29174778. doi:10.1016/j.athoracsur.2017.08.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。